1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by Indication
3.3. Snippet by Route of Administration
3.4. Snippet by End User
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Cases of Neuroendocrine Tumors.
4.1.1.2. Product Approvals.
4.1.1.3. Increase in Research Activities.
4.1.2. Restraints
4.1.2.1. Treatment Side Effects.
4.1.3. Opportunity
4.1.4. Government Initiatives
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. PEST Analysis
5.6. Pipeline Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine Conflict Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Therapy Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.1.2. Market Attractiveness Index, By Therapy Type
10.2. Somatostatin analogs (SSAs)
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Targeted therapy
10.4. Others
11. By Indication
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.1.2. Market Attractiveness Index, By Indication
11.2. Gastrointestinal*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Lungs
11.4. Pancreas
11.5. Others
12. By Route of Administration
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Oral
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Injectable
13. By End User
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.1.2. Market Attractiveness Index, By End User
13.2. Hospitals
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Cancer Research Center
13.4. Ambulatory Surgery Centers
14. By Region
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.7.1. The U.S.
14.2.7.2. Canada
14.2.7.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.7.1. Germany
14.3.7.2. The U.K.
14.3.7.3. France
14.3.7.4. Italy
14.3.7.5. Spain
14.3.7.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.7.1. Brazil
14.4.7.2. Argentina
14.4.7.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.7.1. China
14.5.7.2. India
14.5.7.3. Japan
14.5.7.4. Australia
14.5.7.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
15. Competitive Landscape
15.1. Competitive Scenario
15.2. Market Share Analysis
15.3. Mergers and Acquisitions Analysis
16. Company Profiles
16.1. Pfizer, Inc.
16.1.1. Company Overview
16.1.2. Therapy Type Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. Ipsen Pharmaceuticals
16.3. Novartis
16.4. AVEO Pharmaceuticals, Inc.
16.5. Eli Lilly & Company
16.6. CK Hutchison Holdings (HUTCHMED)
16.7. C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH)
16.8. Lantheus Holdings, Inc.
16.9. Merck & Co., Inc.
16.10. Sanofi
17. Appendix
17.1. About Us and Services
17.2. Contact Us
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
